Auxly Cannabis Group Inc. and IM Cannabis Corp. are facing very different moments, but both situations matter for investors tracking the cannabis sector.
Auxly recently lost out on acquiring Ayurcann’s assets in a court-supervised process, although its financial exposure remains limited due to the deal’s structure. At the same time, IM Cannabis is under pressure to lift its share price after receiving a notice from Nasdaq Stock Market LLC for falling below the minimum bid requirement.
Auxly’s Ayurcann Bid Falls Short, but Downside Remains Limited
Auxly Cannabis Group confirmed that its stalking horse bid wasn’t selected as the winning offer in a court-supervised sale process for the assets of Ayurcann Holdings Corp.
Auxly entered the process with two key elements. The first was the stalking horse bid itself, designed to set a baseline price for competing offers. The second was a debtor-in-possession (DIP) financing facility of up to $2 million, which gave the company a senior secured position over Ayurcann’s assets during the restructuring.
Although another bidder ultimately won the auction, Auxly’s position remains relatively strong. Its offer has been designated as the back-up bid, meaning it could still acquire the assets if the winning transaction fails to close by May 15, 2026.
The DIP facility carries an annual interest rate of 12% and a 2% upfront fee, and is secured by a court-ordered super-priority charge. As part of the closing process with the successful bidder, Auxly expects to be repaid in full, including interest. The company will also receive a break fee and expense reimbursement tied to its role in the sale process.
Strategic Focus Shifts Back to Organic Growth
With the acquisition now uncertain, Auxly appears to be shifting its focus back to internal growth. Management has indicated that the bid was opportunistic and only pursued because it met internal return thresholds. That framing may resonate with investors seeking sustainability amid a challenging cannabis market.
Auxly has also signalled expectations of generating significant free cash flow in 2026. If achieved, this would mark an important step for a sector that has historically struggled with profitability and cash generation. The company is now evaluating how best to deploy capital, balancing potential acquisitions with reinvestment in its core business.
IM Cannabis Receives Nasdaq Notice Over Share Price
At the same time, IM Cannabis Corp. is dealing with a different type of challenge. The company has received a notice from Nasdaq Stock Market LLC stating that it no longer meets the minimum bid price requirement for continued listing.
Under Nasdaq rules, listed companies must maintain a share price of at least $1.00. IM Cannabis has fallen below that threshold, triggering a compliance process. The company now has 180 calendar days, until October 6, 2026, to bring its share price back above the minimum level.
Importantly, the notice doesn’t have an immediate impact on trading. IM Cannabis trading on Nasdaq continues during the compliance period. To regain compliance, the stock must close at or above $1.00 for at least ten consecutive business days.
What Happens if IMC Fails to Regain Compliance
If IM Cannabis doesn’t meet the requirement within the initial 180-day window, it may qualify for an additional 180-day extension. This would depend on meeting other listing standards, including requirements related to market value and publicly held shares.
Should the company fail to regain compliance after the allowed period, Nasdaq could move to delist the stock. In that scenario, IM Cannabis would need to explore alternative trading venues or implement corrective measures such as a reverse stock split to increase its share price.
For now, the company has stated that maintaining its Nasdaq listing is a priority. Management is expected to monitor the share price closely and evaluate available options if the situation does not improve organically.
Rita Ferreira
Rita is a seasoned writer with over five years of experience, having worked with globally renowned platforms, including Forbes and Miister CBD. Her deep knowledge of hemp-related businesses and passion for delivering accurate and concise information distinguish her in the industry. Rita's contributions empower individuals and companies to navigate the complexities of the cannabis world, and her work remains a valuable resource for those seeking a deeper understanding of its potential.
